NPM1 mutations, one of the most common genetic drivers of AML, are now actionable for patients –– Acute unmet need in R/R ...

Two U.S. Food and Drug Administration (FDA)-approved drugs for treating prostate cancer may also be effective against acute ...

Ziftomenib (Komzifti) was approved on Thursday for adults with relapsed/refractory NPM1 -mutated AML who have no satisfactory ...

PRESS RELEASE AI-discovered candidate CHM-029 demonstrates robust, dose-dependent tumor regression in pre-clinical AML models and retains potency ...

Targeting a specialized group of histones is safe and opens new therapeutic opportunities for treating blood cancers, a new ...

New data show that dual-target CAR T therapy induces durable remissions in children with high-risk B-cell leukaemia, offering ...

Acute undifferentiated leukemia is a very rare type of aggressive leukemia — a type of cancer. It’s a very serious condition because researchers don’t know much about it. Leukemia is a type of cancer ...

4A10, a monoclonal antibody targeting interleukin-7 receptor alpha (IL-7Rα; CD127), has received fast track designation from the FDA for the treatment of patients with relapsed or refractory acute ...

Mixed phenotype acute leukemia has qualities of both lymphoid and myeloid leukemias. These mixed qualities make it very difficult to diagnose and treat. The outlook for people with this type of ...